

# UCLA

## UCLA Previously Published Works

### Title

New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review of 2022.

### Permalink

<https://escholarship.org/uc/item/7rj8v10h>

### Journal

OTO Open, 8(1)

### Authors

Wu, Franklin

Gorelik, Daniel

Brenner, Michael

et al.

### Publication Date

2024

### DOI



10.1002/oto2.105

Peer reviewed

# New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review of 2022

OTO Open  
 2024, Vol. 8(1):e105  
 © 2024 The Authors. OTO Open  
 published by Wiley Periodicals LLC  
 on behalf of American Academy of  
 Otolaryngology–Head and Neck  
 Surgery Foundation.  
 DOI: 10.1002/oto.2.105  
<http://oto-open.org>

WILEY

Franklin M. Wu, MD<sup>1</sup> , Daniel Gorelik, MD, MPH<sup>1</sup> ,  
 Michael J. Brenner, MD<sup>2</sup>, Masayoshi Takashima, MD<sup>1</sup>,  
 Amit Goyal, MS, DNB<sup>3</sup>, Ashley E. Kita, MD<sup>4</sup>,  
 Austin S. Rose, MD, MBA<sup>5</sup>, Robert S. Hong, MD, PhD<sup>6,7</sup>,  
 Waleed M. Abuzeid, MD<sup>8</sup>, Peter S. Maria, MD, PhD<sup>9</sup>,  
 Ahmed A. Al-Sayed, MBBS, MTM<sup>10</sup>,  
 Michael E. Dunham, MD, MS<sup>11</sup>, Prajoy Kadkade, MD<sup>12,13</sup>,  
 Scott R. Schaffer, MD<sup>14</sup>, Alan W. Johnson, MD, MS<sup>15</sup>,  
 Adrien A. Eshraghi, MD, MSc<sup>16</sup>,  
 Shireen Samargandy, MBBS<sup>17,18</sup>, Robert J. Morrison, MD<sup>2</sup>,  
 Philip A. Weissbrod, MD<sup>19</sup>, Margaret B. Mitchell, MD, MS<sup>20</sup>,  
 Cyrus C. Rabbani, MD<sup>21</sup>, Neil Futran, MD, DMD<sup>8</sup>, and  
 Omar G. Ahmed, MD<sup>1</sup>

## Abstract

**Objective.** To review new drugs and devices relevant to otolaryngology approved by the Food and Drug Administration (FDA) in 2022.

**Data Sources.** Publicly available FDA data on drugs and devices approved in 2022.

**Review Methods.** A preliminary screen was conducted to identify drugs and devices relevant to otolaryngology. A secondary screen by members of the American Academy of Otolaryngology–Head and Neck Surgery's (AAO-HNS) Medical Devices and Drugs Committee differentiated between minor updates and new approvals. The final list of drugs and devices was sent to members of each subspecialty for review and analysis.

<sup>1</sup>Department of Otolaryngology–Head and Neck Surgery, Houston Methodist Hospital, Houston, USA

<sup>2</sup>Department of Otolaryngology–Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, USA

<sup>3</sup>Department of Otorhinolaryngology, All India Institute of Medical Sciences Jodhpur, Jodhpur, USA

<sup>4</sup>Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, USA

<sup>5</sup>Department of Otolaryngology–Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, USA

<sup>6</sup>Michigan Ear Institute, Farmington Hills, USA

<sup>7</sup>Department of Otolaryngology–Head and Neck Surgery, Wayne State University, Detroit, USA

<sup>8</sup>Department of Otolaryngology–Head and Neck Surgery, University of Washington, Seattle, USA

<sup>9</sup>Department of Otolaryngology–Head and Neck Surgery, Stanford, USA

<sup>10</sup>Department of Otolaryngology–Head & Neck Surgery, King Saud University, Riyadh, Saudi Arabia

<sup>11</sup>Department of Otolaryngology–Head and Neck Surgery, Louisiana State University Health Sciences Center School of Medicine, New Orleans, USA

<sup>12</sup>Department of Surgery, Columbia University–Harlem Hospital, New York City, USA

<sup>13</sup>Department of Surgery, NYU Long Island School of Medicine, New York City, USA

<sup>14</sup>Department of Otorhinolaryngology–Head and Neck Surgery, Hospital University of Pennsylvania, Philadelphia, USA

<sup>15</sup>Department of Otolaryngology–Head & Neck Surgery, Park Nicollet Specialty Care, Bloomington, USA

<sup>16</sup>Department of Otolaryngology and Neurosurgery, University of Miami Miller School of Medicine, Miami, USA

<sup>17</sup>Department of Otolaryngology–Head and Neck Surgery, University of Arizona, Tucson, USA

<sup>18</sup>Department of Otolaryngology–Head and Neck Surgery, King Abdulaziz University, Jeddah, Saudi Arabia

<sup>19</sup>Division of Otolaryngology–Head and Neck Surgery, University of California San Diego, La Jolla, USA

<sup>20</sup>Department of Otolaryngology–Head & Neck Surgery, Harvard Medical School/Mass Eye and Ear, Boston, USA

<sup>21</sup>Department of Otolaryngology–Head and Neck Surgery, Case Western Reserve University and University Hospitals, Cleveland, USA

## Corresponding Author:

Franklin Wu, MD, Houston Methodist Hospital Department of Otolaryngology–Head and Neck Surgery, 6550 Fannin St Floor 17, Houston, TX 77030, USA.

Email: franklinmwu@gmail.com

**Conclusion.** A total of 1251 devices and 37 drugs were identified on preliminary screening. Of these, 329 devices and 5 drugs were sent to subspecialists for further review, from which 37 devices and 2 novel drugs were selected for further analysis. The newly approved devices spanned all subspecialties within otolaryngology. Many of the newly approved devices aimed to enhance patient experience, including over-the-counter hearing aids, sleep monitoring devices, and refined CPAP devices. Other advances aimed to improve surgical access, convenience, or comfort in the operating room and clinic.

**Implications for Practice.** Many new devices and drugs are approved each year to improve patient care and care delivery. By staying up to date with these advances, otolaryngologists can leverage new innovations to improve the safety and quality of care. Given the recent approval of these devices, further studies are needed to assess long-term impact within the field of otolaryngology.

## Keywords

innovation, medical review, new devices

Received October 1, 2023; accepted November 14, 2023.

**M**edical innovation presents opportunities for improving existing therapies, and a wide range of medical technology and therapeutics are continually being developed and brought to market to advance care and address unmet needs. The Food and Drug Administration (FDA) oversees the approval of new medical devices and drugs. This state-of-the-art review evaluates devices and drugs approved in 2022.

## Methods

This review adhered to previously described methodology for assessing new FDA approvals.<sup>1-3</sup> All medical devices and drugs that received FDA approval from January 1 to December 31, 2022 were eligible for inclusion in this review. The FDA provides publicly available databases of records related to approvals for de novo devices, premarket approvals, and 510(k) submissions. Records reviewed by specific committees of the FDA including ENT (ear, nose, and throat), neurosurgery, anesthesia, plastic surgery, and general surgery were assessed along with newly approved drugs. Two independent reviewers completed the initial review of each approval. Further screening and final evaluation for each device and drug was completed by committee members with corresponding subspecialty expertise, assessing novelty, relevance, and impact for the specialty. Companies were contacted for clarification of product details as needed and for permission to reproduce images of products.

## Results

A review of 2022 FDA-approved drugs and devices was conducted. Among these, 112 anesthesia, 98 otolaryngology, 655 general surgery and plastics, and 349 neurosurgery devices were identified and collected, and 37 new drugs approvals were also identified (**Figure 1**). From this group, 954 drugs and devices were removed from an initial screen due to lack of relevance to the field of otolaryngology. From the remaining 329 devices and drugs, 295 were removed in a secondary screen conducted by specialists within otolaryngology. A final list of 37 devices and 2 novel drugs were identified and reviewed by members of the AAO-HNS Medical Devices and Drugs Committee (**Table 1**).

## Discussion

### Otology


#### Over-the-Counter (OTC) Hearing Aids

In August of 2022, the FDA issued a final rule that established a new category of OTC hearing aids. This allowed individuals 18 years and older with mild-to-moderate hearing loss to purchase hearing aids directly from retailers, without the assistance of a hearing health care professional. It provides a regulatory framework for OTC hearing aids, including device design requirements (such as mandating a user-adjustable volume control), safety features (such as providing limits on the maximum sound output), and performance specifications. This rule is intended to both expand access and lower the cost of hearing aids.

While purchase of OTC devices does not require a diagnostic hearing test, OTC hearing aids are not appropriate for individuals with severe or profound hearing loss or those younger than 18 years old, who still require prescription hearing devices. Several devices received FDA approval in the past year, including: Vibe SF (WSAUD A/S), Nuheara IQbuds 2 PRO Hearing Aid (Nuheara Limited), MDHearing Smart Hearing Aid, Jabra Enhance Plus (GN Hearing A/S), Eargo Self-Fitting Hearing Aid (Eargo, Inc. and BHA100 Series Braun Clear Hearing Aid (Kaz USA, Inc.). These FDA changes could allow individuals suffering from hearing loss to have earlier interventions and assistance while they wait for full evaluation with an audiologist and otolaryngologist, potentially reducing the morbidity associated with hearing loss.

#### Otosight Middle Ear Scope

The OtoSight Middle Ear Scope (PhotoniCare) is a video otoscope which allows for direct visualization of the tympanic membrane with optical coherence tomography. The technology also allows physicians to view beyond the tympanic membrane to assess for middle ear pathology.<sup>4</sup> It uses low-coherence light to capture 2D and 3-dimensional (3D) images of the middle ear tissue. The



**Figure 1.** Flowchart of process used to review and determine new Food and Drug Administration-approved devices and drugs in 2022.

technology allows clinicians to visualize past cerumen, other canal obstructions, and opacified tympanic membranes to guide the clinician in evaluating middle ear disease.<sup>5,6</sup> The technology uses low-coherence light to capture 2D and 3D images of the middle ear tissue.

#### OTOPLAN®

OTOPLAN® was developed in close collaboration between MED-EL and CASCINATION AG, and the technology provides a full, 3D reconstruction of the temporal bone to facilitate surgical planning in cochlear implantation surgery (**Figure 2**). OTOPLAN features automatic calculation of preoperative cochlear parameter measurements, which allows surgeons to select electrode arrays according to the specific cochlear anatomy duct length. It also allows surgeons to visualize the potential electrode array position post-op implantation. The software creates reconstructions of the cochlea, round window membrane, bony overhang, semi-circular canals, and internal auditory canal. The software uses image collection from both magnetic resonance imaging and computed tomography scans aiming to provide the most accurate preview of the insertion depth and frequency coverage of each electrode array.<sup>5,6</sup> The software can also give postoperative feedback to visualize and perform a

quality check of the insertion and lead management status. The product has shown success in selection of appropriate CI electrodes in pediatric inner ear malformations.<sup>7,8</sup> It has been proposed that the new version of the software may also be used for BONEBRIDGE placements.

#### Rhinology

##### TruDi Shaver Blade

The TruDi Shaver Blade (Acclarent Inc.) is a single-use, electromagnetically navigated blade intended for use with the Bien-Air S120 Shaver handpiece and OSSEODUO or ORiGO powered systems (Le Noirmont) (**Figure 3**). The blade, available in several configurations, allows for the incision and removal of both soft tissue and bone in otolaryngology and oral-maxillofacial surgery. The device includes 3 and 4 mm straight blades and 4 mm blades with 15°, 40°, and 60° angles. This new shaver blade is also designed for use with the TruDi Navigation System (version 2.3 or later) for 3D image-guided surgery, with distal tip electromagnetic sensor integration. This device offers surgeons another option for a tissue shaver with image guidance capabilities.

**Table 1.** Otolaryngology-Relevant Devices and Drugs Approved by the Food and Drug Administration in 2022 by Subspecialty

	Devices (n = 37)	Drugs (n = 2)
Otology	Over-The-Counter Hearing Aids (6) OtoSight Middle Ear Scope OTOPLAN	None
Rhinology	TruDi Shaver Blade RhinAer Stylus Stryker Intrao-Operative OR Hub (2) VISIONAIR	None
Plastic & Reconstructive Surgery	MIRIA Skin Treatment System	DAXXIFY NexoBrid
Laryngology	Phagenyx Neurostimulation System	None
Head and Neck/Endocrine	Vesseal	None
Sleep	da Vinci E-200 Surgical Generator Sleep Monitoring devices (8) Sunrise SomnoMetry CPAP Devices (4)	None
Pediatrics	Electric Nasal Aspirator	None
General	AG100s Ultrasonic Surgical System Ultrasonic Scalpel System MolecuLightDX ENT-Flex™ Rhinolaryngoscope	None

### RhinAer Stylus

The RhinAer stylus (RhinAer) is an office-based probe used to deliver bipolar radiofrequency energy to tissue in the nasal passages, including areas around the posterior nasal nerve, to treat patients with chronic rhinitis symptoms (**Figure 4**). There are multiple prospective studies including a randomized clinical trial showing improvement in chronic allergic and non-allergic rhinitis symptoms compared to placebo 1 year after treatment.<sup>9–12</sup> The current version incorporates modifications to the stylus that do not change its function, but improve surgeon access and visualization. The updated model has a slimmer shaft and a 10° downward tilt of the tip to minimize visual obstruction and improve access to the posterior middle meatus, particularly in patients with unfavorable anatomy.<sup>13</sup> Further studies to assess efficacy with the new design are needed. This new design will be particularly helpful for clinicians in patients with narrow/obstructive nasal anatomy. The new design will help clinicians maneuver the device around septal deviations, lateral nasal side walls, and more inflamed/edematous mucosa.

### Stryker's Intra-Operative OR Hub

In 2022, Stryker released updates to their intraoperative OR control systems. The SDC4K Information Management System with Device and Voice Control Package is a new version of Stryker's integrative

intraoperative system which allows surgeons and operating room staff to control devices in a hands-free manner with voice commands. The updated version includes a new console with inputs and outputs in HDMI format. These systems allow for greater efficiency during procedures, removing the need to stop surgical progress to adjust certain features. These devices can also capture, store, and display medical device data. The 1688 4K Camera Control Unit with Advanced Imaging Modality 89 and 1688 4K Pendulum Camera Head is also part of Stryker's intraoperative OR Hub. These devices include a camera head and control unit for use with endoscopes or laparoscopes. The devices incorporate a sensor for the camera head, allowing it to rotate the image for the surgeon to maintain orientation. While the literature has not explored the utility of this device, it may be useful in rhinologic or otologic procedures utilizing multiple devices and may have benefits in surgical training. However, these devices require institutional buy-in for a fully interconnected system.

### VISIONAIR™

VISIONAIR™ Rhinoanemometer by PacificMD Biotech is a software application that aims to provide a faster and noninvasive alternative to traditional rhinometry methods such as acoustic rhinometry and anterior rhinomanometry. It uses light reflection technology to map the size



**Figure 2.** The OTOPLAN® surgical planning software.



**Figure 3.** The TruDi® Shaver Blade.

and structure of the nasal airway and applies an artificial intelligence algorithm to measure the cross-sectional area of the nasal valve and cavum from endoscopic images. The system consists of a Windows 10-based smart device, algorithm, and user interface for data entry and display, with the option of storing data locally or to the cloud, while patient information is encrypted and stored anonymously. Although the literature is limited, the device offers a standardized and objective approach to assessing nasal airway patency, which can help clinicians decide on potential surgical candidates and improve

quantification of outcomes following interventions for nasal airway obstruction.<sup>14</sup>

### *Plastic & Reconstructive Surgery*

#### *MIRIA Skin Treatment System®*

MIRIA Skin Treatment System® (AVAVA Inc.) is an intra-dermally focused 1550 nm laser for skin resurfacing and soft tissue coagulation. Clinical indications include aging skin, wrinkles, sun damage, pseudofolliculitis barbae, and deep acne scarring. The MIRIA System's



**Figure 4.** The new RhinAer® stylus.

Focal Point Technology delivers up to 150 mJ of conical energy to the dermis and thus differs from conventional cylindrical lasers. The conical configuration enables clinicians to focus energy delivery to specific depths of the skin, thereby theoretically enhancing the safety across different skin types and pigmentation. Lasers target chromophores in the skin, and melanin can be an unintended chromophore. With traditional lasers, darker skin and higher melanin concentration increase the risk for excess energy absorption, posttreatment hyperpigmentation, and loss of pigment.<sup>15</sup> Patients with darker skin types treated with a 1550 nm laser have increased risk of post-inflammatory hyperpigmentation.<sup>16</sup> The MIRIA Skin Treatment System aims to minimize such risks by focusing the laser energy to a clinician-specified skin depth, allowing a larger maximum pulse energy than predicates (150 vs 70 mJ). Clinical trials are needed to establish if MIRIA's conical technology is superior to EpilME® (2022) or LightSheer® Desire (2017) lasers, which also have FDA clearance for all skin types (Fitzpatrick I-IV).

#### *Anacaulase-bcdb (NexoBrid®)*

NexoBrid® (MediWound), is a bromelain-based (a group of enzymes found in the fruit and stem of the pineapple plant) proteolytic enzyme product that is applied for eschar debridement in adult patients with deep partial or full-thickness thermal burns. Surgical debridement, which reduces bacterial colonization, risk of infection, and nonvital tissue, is the standard of care for burns injuries. However, NexoBrid®, approved in Europe since 2013, is a nonsurgical option for rapid, selective debridement.<sup>17</sup> It has been validated in a multicenter randomized clinical trial and the phase 3 DETECT trial.<sup>18,19</sup> It achieved ≥95% wound closure rate, shorter time to eschar removal versus gel vehicle, and lower blood loss versus surgery. NexoBrid was noninferior to surgery in cosmesis and

function at 12 and 24 months. Utilization of NexoBrid® in the head and neck has been studied in facial burn injuries. In comparisons of NexoBrid® versus surgical debridement for deep facial burns, NexoBrid® significantly improved scar quality, decreased the number of procedures needing complete debridement, and reduced size of autografting necessary after debridement.<sup>19</sup> At 1 year of follow-up, scar quality was improved in the NexoBrid® group compared to surgical debridement. Outcomes in scar quality included pigmentation, pliability, stiffness, thickness, surface area, and scar irregularity. A 2020 European consensus statement highly recommended enzymatic debridement in facial burns with protection of the eyes and facial orifices, further increasing the potential impact of NexoBrid within otolaryngology.<sup>17</sup>

#### *DaxibotulinumtoxinA-lanm DAXXIFY™*

DAXXIFY™ (Revance Therapeutics Inc.) is a long-acting neuromodulator that is FDA-approved in adults for injection to improve moderate to severe glabellar lines from corrugator and/or procerus muscle activity. DAXXIFY™ provides up to double the duration of abobotulinumtoxinA (BOTOX®/BOTOX® Cosmetic), abobotulinumtoxinA (DYSPOUR™), incobotulinumtoxinA (XEOMIN®), rimabotulinumtoxinB (MYOBLOC®), and prabotulinumtoxinA-xvfs (JEUVEAU®). DAXXIFY® contains botulinum toxin type A, which blocks presynaptic acetylcholine release at the neuromuscular junction, with reversible chemical denervation of muscle. It incorporates Peptide Exchange Technology™ (PXT) to stabilize the neuromodulator, allowing prolonged duration of action. Unlike other neuromodulators, it contains no human or bovine serum albumin. DAXXIFY™ was evaluated in the SAKURA study program, which enrolled more than 2700 patients who underwent approximately 4200 treatments.<sup>20–23</sup> In randomized, double-blind, placebo-controlled trials, onset was typically evident within 2 days, and 98% of subjects achieved none or mild wrinkle severity at 4 weeks with a 6-month median duration of defect.<sup>20,21</sup> In open-label phase 3 safety studies, no serious side effects were noted, and most commonly observed adverse reactions were headache (6%), eyelid ptosis (2%), and facial paresis (1%).<sup>22,23</sup>

#### *Laryngology*

##### *Phagenyx® Neurostimulation System for Rehabilitation of Oropharyngeal Dysphagia*

The Phagenyx® Neurostimulation System (Phagenesis Limited) is a device which uses pharyngeal electrical stimulation (PES) to improve pharyngeal swallow function. The device is based on research demonstrating that sensory stimulation results in motor cortex reorganization.<sup>24</sup> The system involves placement of a soft hollow catheter through the nose, advanced through the pharynx to the stomach. The catheter then serves as enteral access for nutrition, while the proximal portion



**Figure 5.** Illustration of Phagenyx® pharyngeal electrical stimulation catheter in place, which can also be used to administer enteral nutrition during treatment.

contains electrodes for pharyngeal electrical stimulation (**Figure 5**). Stimulation is delivered for 10 minutes a day and therapy is recommended for 3 to 6 days. Early randomized controlled studies have demonstrated pharyngeal electrical stimulation may be associated less radiographic aspiration and clinical dysphagia,<sup>25</sup> which has been replicated in a prospective single-arm observational cohort with the Phagenyx device in a neurogenic dysphagia patient population.<sup>26</sup> This may have potential use in our head and neck cancer population post-treatment but further research is needed.

## Head and Neck/Endocrine

### Vesseal™

Vesseal™ (Lydus Medical) is an automated microvascular anastomosis suture deployment system. The needle insertion mechanism contains two-rod protrusions intended to locate, mount, and position the blood vessel relative to the stopper mechanism. Each rod stores 8 curved needles that deploy double-armed nylon sutures. The handle mechanism features right and left switches to deploy the needles on the respective rod side. The delivery needle is taper-pointed stainless steel which can be used for end-to-end anastomosis with sutures ranging from United States Pharmacopeia (USP) sizes 7-0 to 9-0. There are similar devices available in the market such as Perclose ProGlide™.

### Da Vinci E-200 Electrosurgical Generator

The da Vinci E-200 Electrosurgical Generator (Intuitive) allows surgeons to precisely cut, coagulate, and remove

tissue using high-frequency electrical currents in robotic and other minimally invasive surgical procedures.<sup>27</sup> Electrosurgical generators are commonly used in minimally invasive surgeries such as robotic surgery, including transoral procedures for head and neck cancer.<sup>28</sup> Efficient energy instrumentation is crucial for endoscopic minimally invasive surgery. The E-200 Electrosurgical Generator is compatible with a broad range of instruments. It offers multiple high-frequency settings for monopolar and bipolar modes, which can be used for tissue cutting, coagulation, and desiccation. It also has an advanced bipolar radiofrequency mode that is compatible with the da Vinci SynchroSeal and Vessel Sealer Extend advanced energy instruments.

## Sleep

### Improvements and Innovations in Sleep Monitoring for Home Sleep Studies

This past year's FDA-approved developments in sleep apnea technology focused on improving home sleep assessment and improving CPAP compliance. This area is becoming increasingly important for Otolaryngologists who are playing a bigger role in the management of OSA with advent of hypoglossal nerve stimulators. Studies have shown 20% to 50% of single-night sleep testing results in misclassification of OSA severity.<sup>29</sup> Therefore, new at-home technologies allow multi-night testing for capturing the potential night-to-night variability. Among these devices, the Cerebra Sleep System (Cerebra Medical Ltd.), WatchPAT300 (Itamar Medical Ltd.), Nomad PMU810 (Neurotronics), RespiraSense (PMD Solutions), NightOwl (Ectosense NV), BresDX1 (Bresotec Inc.), Onera Sleep Test System (Onera BV), and ANNE Sleep System (Sibel Inc.) (**Figure 6**) offer improvements in data collection, patient comfort, ease of use, and convenience. Many studies have been conducted to validate their accuracy,<sup>30–36</sup> but further research is required to assess performance compared to other devices on the market.

Several devices incorporate artificial intelligence (AI) for measuring and calculating respiratory effort for at-home sleep studies. Sunrise (Sunrise SA) uses AI-powered software along with the measurement of jaw movements through a disposable lightweight 6-channel device that fits



**Figure 6.** ANNE sleep system worn on sternum and finger.





**Figure 7.** Sunrise device worn on the anterior chin.

on the chin (**Figure 7**). Results recently published showed that mandibular jaw movement captured with the Sunrise system is a highly reliable and noninvasive surrogate of the esophageal pressure as the current gold-standard to quantify respiratory effort during sleep.<sup>37–39</sup>

#### *SomnoMetry*

(Neumetry) is an autoscoring artificial intelligence/machine learning (AI/ML) software which automatically analyzes and scores sleep study results. While the technology automates a portion of a sleep study, the results should still be verified and analyzed by a trained physician.

#### *Innovations in CPAP devices*

To improve CPAP compliance, devices have been improved to be more portable with reduced noise. These improvements include intelligent auto-adjustment and humidifier integration with wireless ways to retrieve data (Auto CPAP System by BMC Medical Co., Ltd.), quieter and more portable BiPAP with leak auto-compensation (Luna G3 BPAP System by 3B Medical Inc.), masks that are more form-fitting, moldable, and low profile which allows for optimum mask seal with minimum tension (AirGel Technology with IQ 2 Phantom 2 Nasal Mask by Sleepnet Corp.), as well as stability wings to ensure the masks stay on (Evora Full Face Mask by Fisher & Paykel Health care Ltd.).

#### *Pediatrics*

##### *Electric Nasal Aspirator*

The electric nasal aspirator (Shenzhen XinLianFeng Technology Company, LTD.) is a portable device used to suction excess nasal secretions in children ages 2 to 12. One iteration of the product, which is commercially

available, includes 3 levels of suction and an incorporated music function, with adjustable volume, to help distract and calm young children during use. This is one of many devices available that can help improve nasal airflow and decrease nasal congestion in the pediatric population. This device is useful for parents, but it is important for otolaryngologists to be aware of these technologies. There appear to be potential applications for this new device in the maintenance of nasal hygiene as well as improved management of clinical nasal rhinorrhea, congestion, and obstruction.


#### *General*

##### *AnapnoGuard AG100s Cuff Pressure and Airway Management System*

The AG100s (Hospitech Respiration Ltd.) monitors and controls the cuff pressure of endotracheal and tracheostomy tubes and evacuates secretions from the subglottic space above the cuff during mechanical ventilation. This device automatically maintains cuff pressure pre-set by the user or based on monitoring of carbon dioxide pressure above the cuff. If used with a tube from Hospitech, it can also perform intermittent evacuation of subglottic secretions from above the tube's cuff. The AG100s FDA approval was expanded to include the ability to connect the system to tracheostomy tubes. It is designed to be used with the AnapnoGuard ET tube. This tube helps to address known problems of cuff pressure monitoring and secretion management to avoid complications from tracheostomy tubes.<sup>40</sup> While limited in its portability, the device helps maintain appropriate cuff pressures in patients requiring mechanical ventilation. This has the potential to decrease rates of subglottic and tracheal stenosis and aspiration if pressures are set appropriately below 30 cmH<sub>2</sub>O.

##### *Ultrasonic Surgical Devices*

There are two new ultrasonic surgical dissection devices. The Ultrasonic Scalpel System from SurgNova Health Technologies, is intended for transection, dissection, and ligation soft tissue. This product encompasses 4 components: an energy generator, footswitch, handpiece, and multiple scalpel blades ranging in length from 13 to 43 cm. The UltraSonic Surgical System from Miconvey Technologies Co., Ltd. updates their prior ultrasonic scalpel; this product has similar components, although its scalpel blades range from 1.4 to 4.5 cm and offer additional functions, such as grasping in addition to cutting and coagulating tissue. Compared to other instruments which can cut and cauterize tissue, products utilizing ultrasonic energy may have reduced thermal damage and stronger coagulation properties and allow surgeons to seal vessels up to 8 mm. While described more commonly in laparoscopic literature,<sup>41</sup> these devices have



**Figure 8.** (A) MolecuLightDX™ fluorescence image scanning system. (B) Optical filtering mechanism to only record specific wavelengths of fluorescence signals.



**Figure 9.** The ENT-Flex™ Rhinolaryngoscope with the single-use shell and reusable imaging core.

been used in head and neck procedures as well, including thyroidectomy, free flap harvest, tonsillectomy, and transoral laryngeal cancer resections.<sup>42–45</sup> Data comparing ultrasonic devices to traditional bipolar and cold-steel instruments are limited.

#### *MolecuLightDX™*

MolecuLightDX™ is a fluorescence imaging scanning system that allows the examination and photography of skin wounds, using fluorescence to predict elevated bacterial loads (**Figure 8**). Many studies of this technology have focused on healing of diabetic foot ulcers, although it has also been shown to improve healing in other wounds. It might facilitate the evaluation and treatment of nonhealing wounds, burns, and trauma of the head & neck. The system allows clinicians to take accurate digital wound measurements to allow for greater precision for monitoring wounds.<sup>46–49</sup>

#### *ENT-Flex™ Rhinolaryngoscope*

The ENT-Flex™ Rhinolaryngoscope (Zsquare) is a single-use flexible endoscope featuring a reusable imaging core with a disposable sterile outer shell involving the handle,

steering mechanism, and steerable shaft (**Figure 9**). This scope uses a newly designed single polymeric fiber which allows a smaller optical diameter without compromising resolution. Other endoscopes use complementary metal oxide semiconductor (CMOS) technology with a chip in the distal tip, which limits size and resolution. This new single fiber technology allows for a slim 2.3 mm outer diameter scope, the smallest in the market. This adds to the growing market of single-use endoscopes, which theoretically reduces the risk of cross-contamination and obviates the need for processing or repair costs. This device has not been formally evaluated in the literature. However, the ENT-Flex™ may provide a cost-effective option by offering the outer component with a handle for the physician, effectively providing a barrier for the reusable imaging core while eliminating the need for autoclaving or discarding the entire device.

#### **Limitations**

This study was subject to limitations. While a panel of experts within each subspecialty were consulted to determine which products and drugs should be included in the study, these decisions can be subjective, and there may be disagreements on which devices/drugs should and

should not have been discussed. Furthermore, the potential impact of many of the devices and drugs previously discussed could not be fully elucidated due to the lack of relevant literature currently available. The full impact of many of these innovations will likely not be fully understood until many years later once further studies have been published.

## Implications for Practice

The field of otolaryngology continued to grow and advance in 2022. As otolaryngology progresses, clinicians need to stay abreast of advances in new devices and drugs to optimize care of their patients.

## Author Contributions


**Franklin M. Wu**, data collection, data analysis, manuscript writing, manuscript revisions; **Daniel Gorelik**, data collection, data analysis, manuscript writing, manuscript revisions; **Michael J. Brenner**, data analysis, manuscript writing, manuscript revisions; **Masayoshi Takashima**, data analysis, manuscript writing, manuscript revisions; **Amit Goyal**, data analysis, manuscript writing, manuscript revisions; **Ashley E. Kita**, data analysis, manuscript writing, manuscript revisions; **Austin S. Rose**, data analysis, manuscript writing, manuscript revisions; **Robert S. Hong**, data analysis, manuscript writing, manuscript revisions; **Waleed M. Abuzeid**, data analysis, manuscript writing, manuscript revisions; **Peter S. Maria**, data analysis, manuscript writing, manuscript revisions; **Ahmed A. Al-Sayed**, data analysis, manuscript writing, manuscript revisions; **Michael E. Dunham**, data analysis, manuscript writing, manuscript revisions; **Prajay Kadkade**, data analysis, manuscript writing, manuscript revisions; **Scott R. Schaffer**, data analysis, manuscript writing, manuscript revisions; **Alan W. Johnson**, data analysis, manuscript writing, manuscript revisions; **Adrien A. Eshraghi**, data analysis, manuscript writing, manuscript revisions; **Shireen Samargandy**, data analysis, manuscript writing, manuscript revisions; **Robert J. Morrison**, data analysis, manuscript writing, manuscript revisions; **Philip A. Weissbrod**, data analysis, manuscript writing, manuscript revisions; **Margaret B. Mitchell**, data analysis, manuscript writing, manuscript revisions; **Cyrus C. Rabbani**, data analysis, manuscript writing, manuscript revisions; **Neil Futran**, data analysis, manuscript writing, manuscript revisions; **Omar G. Ahmed**, study design, data collection, data analysis, manuscript writing, manuscript revisions.


## Disclosures

**Competing interests:** Waleed M. Abuzeid, MD, Consultant for Medtronic and Acclarent (Johnson & Johnson). Michael E. Dunham, MD, MS, Partner at Soteria Medical Solutions. Alan W. Johnson, MD, MS, Consultant for Invisian Medical, LLC and receives patent royalties from the University of Minnesota for dental occlusion ties/Minne Ties. Neil Futran, MD, DMD, Educational consultant for Stryker Corporation. Adrien A. Eshraghi, MD, MSc, Research grant from MEDEL GmbH and SoundPharma through the University of Miami.

**Funding source:** None.

## ORCID iD

Franklin M. Wu  <http://orcid.org/0000-0001-7361-401X>

Daniel Gorelik  <http://orcid.org/0000-0001-7998-6949>

## References

1. Rameau A, Hong RS, Djalilian H, et al. New medical device and therapeutic approvals in otolaryngology: state of the art review of 2019. *OTO Open*. 2020;4(2):2473974X20932506. doi:10.1177/2473974X20932506
2. Brenner MJ, Shenson JA, Rose AS, et al. New medical device and therapeutic approvals in otolaryngology: state of the art review 2020. *OTO Open*. 2021;5(4):2473974X211057035. doi:10.1177/2473974X211057035
3. Choi AM, Brenner MJ, Gorelik D, et al. New medical device and therapeutic approvals in otolaryngology: state of the art review of 2021. *OTO Open*. 2022;6(3):2473974X221126495. doi:10.1177/2473974X221126495
4. Teague MS, Nolan RM. Evaluation of the impact of optical coherence tomography on pediatrician otologic examination judgment. *OTO Open*. 2023;7(1):e41. doi:10.1002/oto2.41
5. Vazzana C, Stöver T, Helbig S. Prediction accuracy of cochlear implant electrode insertion depth using a software program. *Laryngorhinotologie*. 2022;101(S02):4-8. doi:10.1055/s-0042-1746820
6. Müller-Graff FT, Voelker J, Kurz A, Hagen R, Neun T, Rak K. Accuracy of radiological prediction of electrode position with otological planning software and implications of high-resolution imaging. *Cochlear Implants Int*. 2023;24:144-154. doi:10.1080/14670100.2022.2159128
7. Li J, Kang S, Du H, et al. Analysis of cochlear parameters in paediatric inner ears with enlarged vestibular aqueduct and patent cochlea. *J Pers Med*. 2022;12(10):1666. doi:10.3390/jpm12101666
8. Zhu H-Y, Sun J-Q, Sun J-W, Guo X-T. The effect of cochlear size on electrically evoked auditory brainstem responses in deaf children. *Laryngoscope Investig Otolaryngol*. 2023;8(2):532-537. doi:10.1002/lio2.1029
9. Ehmer D, McDuffie CM, McIntyre JB, et al. Long-term outcomes following temperature-controlled radiofrequency neurolysis for the treatment of chronic rhinitis. *Allergy Rhinol (Providence)*. 2022;13:215265752210960. doi:10.1177/21526575221096045
10. Ehmer D, McDuffie CM, Scurry WC, et al. Temperature-controlled radiofrequency neurolysis for the treatment of rhinitis. *Am J Rhinol Allergy*. 2022;36(1):149-156. doi:10.1177/19458924211033400
11. Lee JT, Abbas GM, Charous DD, et al. Clinical and quality of life outcomes following temperature-controlled radiofrequency neurolysis of the posterior nasal nerve (RhinAer) for treatment of chronic rhinitis. *Am J Rhinol Allergy*. 2022;36(6):747-754. doi:10.1177/19458924221109987
12. Stolovitzky JP, Ow RA, Silvers SL, Bikhazi NB, Johnson CD, Takashima M. Effect of radiofrequency neurolysis on the symptoms of chronic rhinitis: a randomized controlled

- trial. *OTO Open*. 2021;5(3):2473974X211041124. doi:10.1177/2473974X211041124
13. Fan T, Chandna M, Gorelik D, et al. Correlation between middle turbinate insertion in relation to sphenopalatine foramen and failure rates of cryotherapy and radiofrequency treatment for chronic rhinitis. *Int Forum Allergy Rhinol*. 2023;13(1):88-91. doi:10.1002/alr.23058
  14. Lin JC. Section 510(k) premarket notification of intent; 2022.
  15. Carniol PJ, Woolery-Lloyd H, Zhao AS, Murray K. Laser treatment for ethnic skin. *Facial Plast Surg Clin North Am*. 2010;18(1):105-110. doi:10.1016/j.fsc.2009.11.009
  16. Graber EM, Tanzi EL, Alster TS. Side effects and complications of fractional laser photothermolysis: experience with 961 treatments. *Dermatol Surg*. 2008;34(3):301-307. discussion 305-7 doi:10.1111/j.1524-4725.2007.34062.x
  17. Hirche C, Kreken Almeland S, Dheansa B, et al. Eschar removal by bromelain based enzymatic debridement (Nexobrid®) in burns: European consensus guidelines update. *Burns*. 2020;46(4):782-796. doi:10.1016/j.burns.2020.03.002
  18. Rosenberg L, Shoham Y, Krieger Y, et al. Minimally invasive burn care: a review of seven clinical studies of rapid and selective debridement using a bromelain-based debriding enzyme (Nexobrid®). *Ann Burns Fire Disasters*. 2015;28(4):264-274.
  19. Schulz A, Fuchs PC, Rothermundt I, et al. Enzymatic debridement of deeply burned faces: Healing and early scarring based on tissue preservation compared to traditional surgical debridement. *Burns*. 2017;43(6):1233-1243. doi:10.1016/j.burns.2017.02.016
  20. Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). *Plast Reconstruct Surg*. 2020;145(1):45-58. doi:10.1097/PRS.0000000000006327
  21. Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). *J Am Acad Dermatol*. 2020;82(4):838-845. doi:10.1016/j.jaad.2019.06.1313
  22. Fabi SG, Cohen JL, Green LJ, et al. DaxibotulinumtoxinA for injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. *Dermatol Surg*. 2021;47(1):48-54. doi:10.1097/DSS.0000000000002531
  23. Green JB, Mariwalla K, Coleman K, et al. A large, open-label, phase 3 safety study of daxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study. *Dermatol Surg*. 2021;47(1):42-46. doi:10.1097/DSS.0000000000002463
  24. Hamdy S, Rothwell JC, Aziz Q, Singh KD, Thompson DG. Long-term reorganization of human motor cortex driven by short-term sensory stimulation. *Nat Neurosci*. 1998;1(1):64-68. doi:10.1038/264
  25. Scutt P, Lee HS, Hamdy S, Bath PM. Pharyngeal electrical stimulation for treatment of poststroke dysphagia: individual patient data meta-analysis of randomised controlled trials. *Stroke Res Treat*. 2015;2015:1-8. doi:10.1155/2015/429053
  26. Bath PM, Woodhouse LJ, Suntrup-Krueger S, et al. Pharyngeal electrical stimulation for neurogenic dysphagia following stroke, traumatic brain injury or other causes: main results from the PHADER cohort study. *EClinicalMedicine*. 2020;28:100608. doi:10.1016/j.eclinm.2020.100608
  27. Tokar JL, Barth BA, Banerjee S, et al. Electrosurgical generators. *Gastrointest Endosc*. 2013;78(2):197-208. doi:10.1016/j.gie.2013.04.164
  28. Roselló À, Albuquerque R, Roselló-Llabrés X, Mari-Roig A, Estrugo-Devesa A, López-López J. Transoral robotic surgery vs open surgery in head and neck cancer. A systematic review of the literature. *Medicina Oral Patología Oral y Cirugía Bucal*. 2020;25(5):e599-e607. doi:10.4317/medoral.23632
  29. Lechat B, Naik G, Reynolds A, et al. Multinight prevalence, variability, and diagnostic misclassification of obstructive sleep apnea. *Am J Respir Crit Care Med*. 2022;205(5):563-569. doi:10.1164/rccm.202107-1761OC
  30. Younes M, Soiferman M, Thompson W, Giannouli E. Performance of a new portable wireless sleep monitor. *J Clin Sleep Med*. 2017;13(2):245-258. doi:10.5664/jcsm.6456
  31. Yalamanchali S, Farajian V, Hamilton C, Pott TR, Samuelson CG, Friedman M. Diagnosis of obstructive sleep apnea by peripheral arterial tonometry: meta-analysis. *JAMA Otolaryngol Head Neck Surg*. 2013;139(12):1343-1350. doi:10.1001/jamaoto.2013.5338
  32. Davies C, Lee JY, Walter J, et al. A single-arm, open-label, multicenter, and comparative study of the ANNE sleep system vs polysomnography to diagnose obstructive sleep apnea. *J Clin Sleep Med*. 2022;18(12):2703-2712. doi:10.5664/jcsm.10194
  33. Walter J, Lee JY, Blake S, et al. A new wearable diagnostic home sleep testing platform: comparison with available systems and benefits of multi-night assessments. *J Clin Sleep Med*. 2023;19:865-872. doi:10.5664/jcsm.10432
  34. Montazeri Ghahjaverestan N, Fan W, Aguiar C, Yu J, Bradley TD. Respiratory motion and airflow estimation during sleep using tracheal movement and sound. *Nat Sci Sleep*. 2022;14:1213-1223. doi:10.2147/NSS.S360970
  35. Raschellà F, Knoops-Borm M, Sekeri M, et al. Clinical validation of a wireless patch-based polysomnography system: a pilot study. *medRxiv*. 2022. doi:10.1101/2022.08.04.22278354
  36. Van Pee B, Massie F, Vits S, et al. A multicentric validation study of a novel home sleep apnea test based on peripheral arterial tonometry. *Sleep*. 2022;45(5):5-10. doi:10.1093/sleep/zsac028
  37. Pépin JL, Letesson C, Le-Dong NN, et al. Assessment of mandibular movement monitoring with machine learning

- analysis for the diagnosis of obstructive sleep apnea. *JAMA Netw Open*. 2020;3(1):e1919657. doi:10.1001/jamanetworkopen.2019.19657
38. Le-Dong NN, Martinot JB, Coumans N, et al. Machine learning-based sleep staging in patients with sleep apnea using a single mandibular movement signal. *Am J Respir Crit Care Med*. 2021;204(10):1227-1231. doi:10.1164/rccm.202103-0680LE
39. Pepin JL, Le-Dong NN, Cuthbert V, et al. Mandibular movements are a reliable noninvasive alternative to esophageal pressure for measuring respiratory effort in patients with Sleep Apnea Syndrome. *Nat Sci Sleep*. 2022;14:635-644. doi:10.2147/NSS.S346229
40. Saadatmand V. Inner lumen tracheostomy tube capable of continuous monitoring of cuff pressure. *J Biomed Phys Eng*. 2021;11(6):757-760. doi:10.31661/jbpe.v0i0.2012-1247
41. Crispi CP, Crispi CP, da Silva Reis PS, Mendes FLF, Filgueiras MM, de Freitas Fonseca M. Hemostasis with the ultrasonic scalpel. *J Soc Laparoendosc Surg*. 2018;22(4):e201800042. doi:10.4293/JLSL.2018.00042
42. Sarda H, Arora V, Sachdeva T, Jain SK. Systematic review of comparison of use of ultrasonic scalpel versus conventional haemostatic techniques in performing thyroid surgery. *Indian J Otolaryngol Head Neck Surg*. 2022;74(Suppl 3):6285-6291. doi:10.1007/s12070-021-03026-5
43. Dean NR, Rosenthal EL, Morgan BA, Magnuson JS, Carroll WR. Harmonic scalpel versus electrocautery and surgical clips in head and neck free-flap harvesting. *Ear Nose Throat J*. 2014;93(6):36-39.
44. Neumann C, Street I, Lowe D, Sudhoff H. Harmonic scalpel tonsillectomy: a systematic review of evidence for postoperative hemorrhage. *Otolaryngol Head Neck Surg*. 2007;137(3):378-384. doi:10.1016/j.otohns.2007.05.003
45. Tirelli G, Gardenal N, Gatto A, Bonini P, Tofanelli M, Fernández-Fernández MM. Is there a role for ultrasonic surgery in transoral laryngeal cancer resections? *Expert Rev Med Devices*. 2019;16(4):275-279. doi:10.1080/17434440.2019.1596795
46. Andersen CA, McLeod K, Steffan R. Diagnosis and treatment of the invasive extension of bacteria (cellulitis) from chronic wounds utilising point-of-care fluorescence imaging. *Int Wound J*. 2022;19(5):996-1008. doi:10.1111/iwj.13696
47. Farhan N, Jeffery S. Diagnosing burn wounds infection: the practice gap and advances with MolecuLight bacterial imaging. *Diagnostics (Basel, Switzerland)*. 2021;11(2):11. doi:10.3390/diagnostics11020268
48. Rennie M, Dunham D, Lindvere-Teene L, Raizman R, Hill R, Linden R. Understanding real-time fluorescence signals from bacteria and wound tissues observed with the MolecuLight i:X. *Diagnostics*. 2019;9(1):22. doi:10.3390/diagnostics9010022
49. Rennie MY, Lindvere-Teene L, Tapang K, Linden R. Point-of-care fluorescence imaging predicts the presence of pathogenic bacteria in wounds: a clinical study. *J Wound Care*. 2017;26(8):452-460. doi:10.12968/jowc.2017.26.8.452